Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

cating and spreading within solid tumors (whilst leaving healthy cells unaffected), causing the death of cancer cells; and through stimulating the immune system to destroy un-injected metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEX (GM-CSF) has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date. Previous clinical trials have enrolled patients with breast cancer, melanoma, and pancreatic cancer in addition to head and neck cancer, with indications of clinical activity being observed in each. The Company recently commenced a Phase III study in metastatic melanoma following the achievement of an unprecedented proportion of durable complete remissions in a Phase II study using OncoVEX (GM-CSF) as stand alone therapy. An overview of the Phase II melanoma results is available on our website.

The Company's second program is a vaccine for genital herpes, ImmunoVEX (HSV2), which provides complete protection in animal models of the disease. The vaccine has been authorized to commence clinical testing in the UK.

For further information, please go to www.biovex.com.


'/>"/>
SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... (PRWEB) April 23, 2015 The ... intends to conduct a groundbreaking pilot study to ... be reversed in as little as three to ... of metabolic and nutritional medicine—will aggressively target and ... and destroy our aging brain. These include oxidative ...
(Date:4/23/2015)... Six startups from Russia traveled to ... part of the U.S.-Russia Innovation Corridor (USRIC) program. ... startups to participate in the program since the ... University of Maryland (UMD) signed a Memorandum of ... in the biomedical industry in 2013. , Supported ...
(Date:4/23/2015)... April 23, 2015 Follow ... to a series of genetic tests that determine ... Lou Gehrig's disease, Huntington's disease, and Alzheimer's disease. ... gene composition and interaction in diseased tissue/cells to ... well as the response to treatment, such as ...
(Date:4/23/2015)... -- Prospects for Leading Companies in OTC, ...   We predict the global healthcare packaging ... 2015 and will grow at a CAGR of 6.3% between ... the world and increasing functional requirements for healthcare packaging products ... healthcare packaging market. A global ageing population, changing ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10
... National Institute of Standards and Technology (NIST), in ... (NASA), has published detailed guidelines* for making essential ... The new guide constitutes the current best practices ... heavily studied of the new generation of nanoscale ...
... Mr. Glynn has over 34 years of,combined financial, ... the life sciences industry for his role in the ... Glynn,retired from Invitrogen Corporation (Nasdaq: IVGN ) in ... several operating roles including CFO,President and COO and CEO. ...
... shows naturally occurring antibodies contained in, GAMMAGARD ... Alzheimer,s disease, CHICAGO, April 15 The ... Inc. (NYSE: BAX ) today,announced data from ... LIQUID [Immune Globulin Intravenous (Human)] (IGIV),marketed as KIOVIG ...
Cached Biology Technology:Carbon nanotube measurements: latest in NIST 'how-to' series 2eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... leftovers. A research study appearing in the April 2009 ... ( http://www.jleukbio.org ) sheds light on one cause of ... States and The Netherlands show that a specific gene ... leftover remnants of bacteria cell walls, called muramyl dipeptide ...
... San Diego, CA (March 31, 2009) Novocell, Inc., ... has received U.S. Patent 7,510,876 with claims covering human ... only pancreatic type cells, which Novocell is developing for ... other endoderm lineage-derived tissues and organs such as lungs, ...
... University master,s graduate is working with doctors at Vanderbilt ... microscope that could someday reduce the number of biopsies ... the skin often prompt dermatologists to remove skin samples ... to diagnose skin cancers, said Chris Arrasmith, who recently ...
Cached Biology News:Bad mix of bacterial remnants and genetics leads to arthritis 2Montana State grad's work helps diagnose skin cancer without a biopsy 2Montana State grad's work helps diagnose skin cancer without a biopsy 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Biology Products: